

## DAFTAR PUSTAKA

- Abd Elhamid, A. H., Mohamed, A. a. E. A. & Khattab, A. M. 2020. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial. *BMC Ophthalmol.*, 20, 1-9.
- Alagöz, C., Yıldırım, Y., Kocamaz, M., Baz, Ö., Çiçek, U., Çelik, B., Demirkale, H. İ., Yazıcı, A. T. & Taşkapılı, M. 2016. The efficacy of intravitreal bevacizumab in vitreous hemorrhage of diabetic subjects. *Turk. J. Ophthalmol.*, 46, 221.
- Antoszyk, A. N., Glassman, A. R., Beaulieu, W. T., Jampol, L. M., Jhaveri, C. D., Punjabi, O. S., Salehi-Had, H., Wells, J. A., Maguire, M. G. & Stockdale, C. R. 2020. Effect of intravitreal aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic Retinopathy: a randomized clinical trial. *JAMA*, 324, 2383-2395.
- Arevalo, J. F., Lasave, A. F., Wu, L., Maia, M., Diaz-Llopis, M., Alezzandrini, A. A. & Brito, M. 2017. Intravitreal bevacizumab for proliferative diabetic retinopathy. *Retina*, 37, 334-343.
- Bandello, F., Zarbin, M. A., Lattanzio, R. & Zucchiatti, I. 2016. *Clinical Strategies in the Management of Diabetic Retinopathy*, Springer.
- Belin, P. J. & Parke Iii, D. W. 2020. Complications of vitreoretinal surgery. *Curr. Opin. Ophthalmol.*, 31, 167-173.
- Berrocal, M. H. & Acaba-Berrocal, L. 2021. Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature. *Curr. Opin. Ophthalmol.*, 32, 203-208.
- Choovuthayakorn, J., Khunsongkiet, P., Patikulsila, D., Watanachai, N., Kunavisarut, P., Chaikitmongkol, V. & Ittipunkul, N. 2019. Characteristics and outcomes of pars plana vitrectomy for proliferative diabetic retinopathy patients in a Limited Resource Tertiary Center over an eight-year period. *J. Ophthalmol.*, 2019.
- Constantin, B. D., Andrei, B. & Andreea, M. 2016. Vitrectomy surgery of diabetic retinopathy complications. *Rom. J. Ophthalmol.*, 60, 31.
- Dahlan, M. S. 2009. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan, Edisi 3*, Jakarta, Salemba Medika.
- Ding, Y., Yao, B., Hang, H. & Ye, H. 2020. Multiple factors in the prediction of risk of recurrent vitreous haemorrhage after sutureless vitrectomy for non-clearing vitreous haemorrhage in patients with diabetic retinopathy. *BMC Ophthalmol.*, 20, 1-7.
- Duh, E. J., Sun, J. K. & Stitt, A. W. 2017. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. *JCI insight*, 2.
- El Annan, J. & Carvounis, P. E. 2014. Current management of vitreous hemorrhage due to proliferative diabetic retinopathy. *Int. Ophthalmol. Clin.*, 54, 141.

- Falavarjani, K. G. & Nguyen, Q. 2013. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. *Eye*, 27, 787-794.
- Farhood, Q. K. & Twfeeq, S. M. 2014. Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients. *Clinical Ophthalmology (Auckland, NZ)*, 8, 599.
- Fassbender, J. M., Ozkok, A., Canter, H. & Schaal, S. 2016. A comparison of immediate and delayed vitrectomy for the management of vitreous hemorrhage due to proliferative diabetic retinopathy. *Ophthalmic. Surg. Lasers Imaging*, 47, 35-41.
- Hou, Y., Cai, Y., Jia, Z. & Shi, S. 2020. Risk factors and prevalence of diabetic retinopathy: A protocol for meta-analysis. *Medicine*, 99.
- Iuliano, L., Corbelli, E., Bandello, F. & Codenotti, M. 2022. Protective effect of vitrectomy on the course of diabetic retinopathy: A case report. *Eur. J. Ophthalmol.*, 32, NP177-NP180.
- Lechner, J., O'leary, O. E. & Stitt, A. W. 2017. The pathology associated with diabetic retinopathy. *Vision Res.*, 139, 7-14.
- Lee, B. J. & Yu, H. G. 2010. Vitreous hemorrhage after the 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. *Retina*, 30, 1671-1677.
- Lieberman Ronni, M., Gow, J. & Grillone, L. 2006. Development and Implementation of a Vitreous Hemorrhage Grading Scale. *Retinal Physician, Issue: May*.
- Lo, W. R., Kim, S. J., Aaberg Sr, T. M., Bergstrom, C., Srivastava, S., Yan, J., Martin, D. F. & Hubbard Iii, G. B. 2009. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). *Retina (Philadelphia, Pa.)*, 29, 926.
- Mahalingam, P., Topiwalla, T. T. & Ganesan, G. 2018. Vitreous rebleed following sutureless vitrectomy: incidence and risk factors. *Indian J. Ophthalmol.*, 66, 558.
- Mansoori, T., Agraharam, S. G., Manwani, S. & Balakrishna, N. 2021. Intraocular pressure changes after intravitreal bevacizumab or ranibizumab injection: A retrospective study. *Journal of current ophthalmology*, 33, 6.
- Moradian, S., Ahmadieh, H., Malihi, M., Soheilian, M., Dehghan, M. H. & Azarmina, M. 2008. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. *Graefe's Archive for Clinical and Experimental Ophthalmology*, 246, 1699-1705.
- Nawaz, I. M., Rezzola, S., Cancarini, A., Russo, A., Costagliola, C., Semeraro, F. & Presta, M. 2019. Human vitreous in proliferative diabetic retinopathy: characterization and translational implications. *Prog. Retin. Eye Res.*, 72, 100756.
- Parameswarappa, D. C., Rajalakshmi, R., Mohamed, A., Kavya, S., Munirathnam, H., Manayath, G., Kumar, M. A., Raman, R., Vignesh, T. & Ramasamy, K. 2021. Severity of diabetic retinopathy and its relationship with age at onset of diabetes mellitus in India: A multicentric study. *Indian J. Ophthalmol.*, 69, 3255.

- Petermeier, K., Szurman, P., Bartz-Schmidt, U. & Gekeler, F. 2010. Pathophysiology of cataract formation after vitrectomy. *Klinische Monatsblätter für Augenheilkunde*, 227, 175-180.
- Ratnarajan, G., Mellington, F., Saldanha, M., De Silva, S. & Benjamin, L. 2011. Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage. *Eye*, 25, 704-709.
- Ronald, D. P. & Matthew, D. D. 2008. Proliferative Diabetic Retinopathy. In: DUH (ed.) *Diabetic Retinopathy*. USA: Humana Press.
- Sampat, K. M. & Garg, S. J. 2010. Complications of intravitreal injections. *Curr. Opin. Ophthalmol.*, 21, 178-183.
- Sasongko, M. B., Widyaputri, F., Agni, A. N., Wardhana, F. S., Kotha, S., Gupta, P., Widayanti, T. W., Haryanto, S., Widyaningrum, R. & Wong, T. Y. 2017. Prevalence of diabetic retinopathy and blindness in Indonesian adults with type 2 diabetes. *Am. J. Ophthalmol.*, 181, 79-87.
- Smiddy, W. E. & Flynn Jr, H. W. 1999. Vitrectomy in the management of diabetic retinopathy. *Surv. Ophthalmol.*, 43, 491-507.
- Stewart, M. W. 2017a. The Diabetic Retina: Anatomy and Pathophysiology. *Diabetic Retinopathy Current Pharmacologic Treatment and Emerging Strategies*. Singapore: Springer Nature Singapore Pte Ltd.
- Stewart, M. W. 2017b. Treatment of Diabetic Retinopathy: A Historical Perspective. *Diabetic Retinopathy Current Pharmacologic Treatment and Emerging Strategies*. Singapore: Springer Nature Singapore Pte Ltd.
- Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., Mckay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P. & Simo, R. 2016. The progress in understanding and treatment of diabetic retinopathy. *Prog. Retin. Eye Res.*, 51, 156-186.
- Teo, Z. L., Tham, Y.-C., Yu, M. C. Y., Chee, M. L., Rim, T. H., Cheung, N., Bikbov, M. M., Wang, Y. X., Tang, Y. & Lu, Y. 2021. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. *Ophthalmology*.
- Tolentino, M. 2011. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv. Ophthalmol.*, 56, 95-113.
- Van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, H. S., Mura, M., Goldschmeding, R., Van Noorden, C. J., Klaassen, I. & Schlingemann, R. O. 2012. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. *Br. J. Ophthalmol.*, 96, 587-590.
- Wang, W. & Lo, A. C. 2018. Diabetic retinopathy: pathophysiology and treatments. *Int. J. Mol. Sci.*, 19, 1816.
- Zhao, Y. & Singh, R. P. 2018. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. *Drugs in context*, 7.